Key facts
- Aevumed’s last known valuation is $46.1M (Jun 2025).
- It has raised $6.3M across 4 recorded rounds; the latest was Seed Round ($3.0M) in Dec 2021.
- Notable investors include Ben Franklin Technology Partners of Southeastern Pennsylvania, Chemical Angel Network.
- Aevumed has filed 4 Form Ds with the SEC, most recently Jun 2025 ($3.0M sold to 36 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 4 rounds
- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Aevumed
Funding rounds
4 roundsAbout Aevumed
Developer of a medical device designed to provide treatment for rotator cuff tears. The company's device offers pull-out strength and suture retention to improve healing between the tendon and bone, enabling patients to acquire mechanical support and biological enhancement to address the failure of tendon retear rates in rotator cuff surgeries.
- Sector
- Healthcare
- HQ
- Malvern, PA, United States
- Founded
- 2013
- Employees
- 9
- Website
- aevumed.com/
- Ownership
- Privately Held (backing)
Aevumed doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Aevumed shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Aevumed in its N-PORT filings yet. We sweep new filings monthly.